Literature DB >> 19176207

Myeloid growth factors.

Jeffrey Crawford1, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W Blayney, Spero R Cataland, David C Dale, George D Demetri, Harry P Erba, James Foran, Alison G Freifeld, Marti Goemann, Mark L Heaney, Sally Htoy, Susan Hudock, Dwight D Kloth, David J Kuter, Gary H Lyman, Laura Boehnke Michaud, Sarah C Miyata, Martin S Tallman, Saroj Vadhan-Raj, Peter Westervelt, Michael K Wong.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19176207     DOI： 10.6004/jnccn.2009.0006

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  12 in total

1.  Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.

Authors:  Nicole M Kuderer; Gary H Lyman
Journal:  J Natl Cancer Inst       Date:  2011-06-13       Impact factor: 13.506

2.  Polypharmacy and the management of the older cancer patient.

Authors:  L Balducci; D Goetz-Parten; M A Steinman
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

3.  Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.

Authors:  Gary H Lyman; Nicole M Kuderer; Jeffrey Crawford; Debra A Wolff; Eva Culakova; Marek S Poniewierski; David C Dale
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

4.  How we treat febrile neutropenia in patients receiving cancer chemotherapy.

Authors:  Gary H Lyman; Kenneth V I Rolston
Journal:  J Oncol Pract       Date:  2010-05       Impact factor: 3.840

Review 5.  Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor.

Authors:  Alejandro Francisco-Cruz; Miguel Aguilar-Santelises; Octavio Ramos-Espinosa; Dulce Mata-Espinosa; Brenda Marquina-Castillo; Jorge Barrios-Payan; Rogelio Hernandez-Pando
Journal:  Med Oncol       Date:  2013-11-22       Impact factor: 3.064

6.  American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

Authors:  Gary H Lyman; Marc Carrier; Cihan Ay; Marcello Di Nisio; Lisa K Hicks; Alok A Khorana; Andrew D Leavitt; Agnes Y Y Lee; Fergus Macbeth; Rebecca L Morgan; Simon Noble; Elizabeth A Sexton; David Stenehjem; Wojtek Wiercioch; Lara A Kahale; Pablo Alonso-Coello
Journal:  Blood Adv       Date:  2021-02-23

Review 7.  Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?

Authors:  Anna Rachelle Mislang; Laura Biganzoli
Journal:  Cancers (Basel)       Date:  2015-07-03       Impact factor: 6.639

8.  Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.

Authors:  P Trueman
Journal:  Br J Cancer       Date:  2009-09       Impact factor: 7.640

Review 9.  Exogenous endothelial cells as accelerators of hematopoietic reconstitution.

Authors:  J Christopher Mizer; Thomas E Ichim; Doru T Alexandrescu; Constantin A Dasanu; Famela Ramos; Andrew Turner; Erik J Woods; Vladimir Bogin; Michael P Murphy; David Koos; Amit N Patel
Journal:  J Transl Med       Date:  2012-11-21       Impact factor: 5.531

10.  Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.

Authors:  Didier Kamioner; Stefan Fruehauf; Fréderic Maloisel; Laurent Cals; Stéphane Lepretre; Christian Berthou
Journal:  BMC Cancer       Date:  2013-11-16       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.